Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

A. Blauvelt; C. Paul; P. van de Kerkhof; R. B. Warren; A. B. Gottlieb; R. G. Langley; F. Brock; C. Arendt; M. Boehnlein; M. Lebwohl; K. Reich

doi:10.1111/bjd.19314

Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

A. Blauvelt, C. Paul, P. van de Kerkhof, R. B. Warren, A. B. Gottlieb, R. G. Langley, F. Brock, C. Arendt, M. Boehnlein, M. Lebwohl, K. Reich

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	640-651
Number of pages	12
Journal	British Journal of Dermatology
Volume	184
Issue number	4
DOIs	https://doi.org/10.1111/bjd.19314
Publication status	Published - Apr 2021

ASJC Scopus Subject Areas

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjd.19314

Cite this

Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R. B., Gottlieb, A. B., Langley, R. G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., & Reich, K. (2021). Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. British Journal of Dermatology, 184(4), 640-651. https://doi.org/10.1111/bjd.19314

Blauvelt, A, Paul, C, van de Kerkhof, P, Warren, RB, Gottlieb, AB, Langley, RG, Brock, F, Arendt, C, Boehnlein, M, Lebwohl, M & Reich, K 2021, 'Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies', British Journal of Dermatology, vol. 184, no. 4, pp. 640-651. https://doi.org/10.1111/bjd.19314

@article{e489658536eb42de9e690fead364758e,

title = "Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies",

author = "A. Blauvelt and C. Paul and {van de Kerkhof}, P. and Warren, {R. B.} and Gottlieb, {A. B.} and Langley, {R. G.} and F. Brock and C. Arendt and M. Boehnlein and M. Lebwohl and K. Reich",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists",

year = "2021",

month = apr,

doi = "10.1111/bjd.19314",

language = "English",

volume = "184",

pages = "640--651",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Long-term safety of certolizumab pegol in plaque psoriasis

T2 - pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

AU - Blauvelt, A.

AU - Paul, C.

AU - van de Kerkhof, P.

AU - Warren, R. B.

AU - Gottlieb, A. B.

AU - Langley, R. G.

AU - Brock, F.

AU - Arendt, C.

AU - Boehnlein, M.

AU - Lebwohl, M.

AU - Reich, K.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85090212642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090212642&partnerID=8YFLogxK

U2 - 10.1111/bjd.19314

DO - 10.1111/bjd.19314

M3 - Article

C2 - 32531798

AN - SCOPUS:85090212642

SN - 0007-0963

VL - 184

SP - 640

EP - 651

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -

Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this